Cargando…

Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer

Most prostate cancer patients will progress to a castration-resistant state (CRPC) after androgen ablation therapy and despite the development of new potent anti-androgens, like enzalutamide (ENZ), which prolong survival in CRPC, ENZ-resistance (ENZ(R)) rapidly occurs. Re-activation of the androgen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thaper, Daksh, Vahid, Sepideh, Kaur, Ramandeep, Kumar, Sahil, Nouruzi, Shaghayegh, Bishop, Jennifer L., Johansson, Martin, Zoubeidi, Amina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251893/ https://www.ncbi.nlm.nih.gov/pubmed/30470788 http://dx.doi.org/10.1038/s41598-018-35612-z

Ejemplares similares

The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer
por: Vahid, Sepideh, et al.
Publicado: (2016)

ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer
por: Nouruzi, Shaghayegh, et al.
Publicado: (2022)

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2015)

Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L, et al.
Publicado: (2013)

STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population
por: Canesin, Giacomo, et al.
Publicado: (2020)

Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells
por: Hellsten, Rebecka, et al.
Publicado: (2011)

The STAT3 inhibitor galiellalactone inhibits the generation of MDSC‐like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
por: Hellsten, Rebecka, et al.
Publicado: (2019)

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
por: Toren, Paul, et al.
Publicado: (2016)

Local and systemic modulation of the PD-L1 pathway is a novel mechanism of Enzalutamide resistance in castration-resistant prostate cancer
por: Bishop, Jennifer, et al.
Publicado: (2014)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer
por: Ko, Hyejin, et al.
Publicado: (2019)

Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity
por: Monga, Jitender, et al.
Publicado: (2021)

Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer
por: Lounis, Mohamed Amine, et al.
Publicado: (2020)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells
por: García, Víctor, et al.
Publicado: (2015)

Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia
por: Melong, Nicole, et al.
Publicado: (2017)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells
por: Han, Yangyang, et al.
Publicado: (2017)

Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT
por: Liu, Qiuli, et al.
Publicado: (2017)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Anti-Inflammatory and Anti-Thrombotic Effects of the Fungal Metabolite Galiellalactone in Apolipoprotein E-Deficient Mice
por: Bollmann, Franziska, et al.
Publicado: (2015)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
por: Simon, Iris, et al.
Publicado: (2021)

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
por: Erb, Holger H. H., et al.
Publicado: (2020)

The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
por: Hellsten, Rebecka, et al.
Publicado: (2022)

Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer
por: Zardan, A, et al.
Publicado: (2014)

The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide
por: Gray, Jaimie S., et al.
Publicado: (2023)

LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects
por: Duprat, Felix, et al.
Publicado: (2023)

Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models
por: Sooreshjani, Moloud Aflaki, et al.
Publicado: (2021)

RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2021)

Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2023)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016)

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway
por: Luo, Yong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qeep31unn7v27ln076qr7kpit8